Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40

CARDINAL HEALTH INC

2024-FY EPS reported $1.07 revenue$167,119,000,000

Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).
Pharma & Specialty Solutions segment profit $580M (+4%); Global Medical Products segment profit $20M vs -$46M a year ago.
FY2024 non-GAAP EPS guidance raised to $7.30-$7.40 (from $7.20-$7.35); non-GAAP effective tax rate guidance lowered to 22%-23%.
Preliminary FY2025 non-GAAP EPS guidance at least $7.50; Pharma segment profit growth at least 1%; GMPD segment profit ~$175M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CARDINAL HEALTH INC reported third quarter fiscal year 2024 results: revenue $54.9 billion, net income $258 million, EPS $1.05. Guidance raised.

Period: third quarter fiscal year 2024
Revenue: $54.9 billion
Net income: $258 million
EPS: $1.05
Guidance: raised
Result: reported results

Exact text from the filing

Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance • Revenue increased 9% to $54.9 billion • GAAP 1 operating earnings were $367 million; GAAP diluted EPS was $1.05 • Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 • Fiscal year 2024 non-GAAP EPS guidance 2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 • Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0000721371-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.